SAVA Deadline: SAVA Investors Have Opportunity to Lead Cassava Sciences, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Cassava Sciences, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought Cassava securities between February 7, 2024, and November 24, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by February 10, 2025 [3]. - The lawsuit alleges that Cassava Sciences misrepresented the reliability of information regarding its drug prospects and downplayed risks associated with its leading drug candidate, simufilam [5]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4]. Group 3: Case Background - The lawsuit claims that Cassava Sciences created a false impression of confidence in simufilam's potential to treat Alzheimer's Disease, despite lacking evidence to support such claims [5]. - When the true nature of the drug's efficacy became known, investors reportedly suffered damages as a result of the misleading information [5].